Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313962 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
A Phase 1 study, sponsored by Autoimmune Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01313962 is a Phase 1 study that has completed, run by Autoimmune Technologies. The registered enrollment target is 32 participants.
The verdict
NCT01313962, a Phase 1 study, has completed, sponsored by Autoimmune Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.
Interventions
- OTHER Placebo
- DRUG Flufirvitide-3 0.05 mg single dose
- DRUG Flufirvitide-3, 0.1 mg single dose
- DRUG Flufirvitide-3, 0.2 mg single dose
- DRUG Flufirvitide-3, 0.4 mg single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313962
The ClinicalTrials.gov registry entry for NCT01313962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autoimmune Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01313962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313962 about?
NCT01313962 is a clinical study titled "Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects". The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.
What is the current status of trial NCT01313962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01313962?
The interventions under investigation include: Placebo (OTHER), Flufirvitide-3 0.05 mg single dose (DRUG), Flufirvitide-3, 0.1 mg single dose (DRUG), Flufirvitide-3, 0.2 mg single dose (DRUG), Flufirvitide-3, 0.4 mg single dose (DRUG).
Who is sponsoring clinical trial NCT01313962?
This trial is sponsored by Autoimmune Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.